1. A porous membrane for a secondary battery, comprising non-conductive particles and a binder for a porous membrane, wherein
the non-conductive particle is a polymer particle having a core-shell structure,
the non-conductive particle has a core portion having a glass transition point of 30\xb0 C. to 90\xb0 C.,
the non-conductive particle has a shell portion having a glass transition point higher than that of the core portion by 10\xb0 C. or higher,
a thickness of the shell portion is 0.01% to 3.0% of a number average particle diameter of the non-conductive particles, and
a number average particle diameter (A) of the non-conductive particle and a number average particle diameter (B) of the binder for a porous membrane satisfy (A)>(B).
2. The porous membrane for a secondary battery according to claim 1, wherein the shell portion of the non-conductive particles and the binder for a porous membrane contain 50% by weight or more of (meth)acrylate unit.
3. The porous membrane for a secondary battery according to claim 1, wherein the non-conductive particles have a number average particle diameter of 100 nm to 1,500 nm.
4. A method for producing the porous membrane for a secondary battery according to claim 1, comprising:
mixing the non-conductive particles, the binder for a porous membrane, and a medium to prepare a slurry for a porous membrane;
applying the slurry for a porous membrane onto a substrate to form a slurry layer; and
drying the slurry layer.
5. The method according to claim 4, wherein
the medium is an aqueous medium, and
the slurry for a porous membrane is an aqueous dispersion.
6. An electrode for a secondary battery, comprising:
a current collector;
an electrode material layer that contains an electrode active material and a binding agent for an electrode material layer, and adheres to the current collector, and
the porous membrane according to claim 1 that is formed on the electrode material layer.
7. A separator for a secondary battery, comprising:
an organic separator; and
the porous membrane according to claim 1 that is formed on the organic separator.
8. A secondary battery comprising a positive electrode, a negative electrode, a separator, and an electrolytic solution, wherein
at least any one of the positive electrode, the negative electrode, and the separator has the porous membrane according to claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula I
112
in which:
W is R1ABDC(R16), R1ABDC(R16)C,
113
with it being possible for the ring systems
114
to contain 1 or
2 heteroatoms from the group N, O and S, to be saturated or unsaturated, once or more than once, and be substituted by 1-3 substituents from R16 or substituted, once or twice, by doubly bonded O or S;
Y is CO, CS or CH2;
Z is N(R0), O, S or CH2;
A is a direct linkage, (C1-C8)-alkanediyl, NR2NCR2, NR2C(O)NR2, NR2C(O)O, NR2C(O)S, NR2C(S)NR2, NR2C(S)O, NR2C(S)S, NR2S(O)nNR2, NR2S(O)nO, NR2S(O)n, (C3-C12)-cycloalkanediyl, CC, NR2C(O), C(O)NR2, (C5-C14)-arylene-C(O)NR2, O, S(O), (C5-C14)-arylene-, CO, (C5-C14)-arylene-CO, NR2, SO2NR2,C(O)O, OC(O), NCR2, R2CN, CR2CR3or (C5-C14)-arylene-S(O)n, which in each case can be substituted by NR2 andor substituted, once or twice, by (C1-C8)-alkanediyl;
B is a direct linkage, (C1-C8)-alkanediyl, (C5-C10)-arylene, (C3-C8)-cycloalkanediyl, CC, NR2, C(O), NR2C(O), C(O)NR2, NR2C(O)NR2, NR2C(S)NR2, OC(C), C(O)O, S(C), S(O)2, S(O)NR2, S(O)2NR2, NR2S(O), NR2S(O)2, O, S or CR2CR3, which in each case can be substituted once or twice by (C1-C6)-alkanediyl, or is a divalent radical of a 5- or 6-membered saturated or unsaturated ring which contains 1 or 2 nitrogen atoms and can be substituted, once or twice, by (C1-C6)-alkyl or doubly bonded oxygen or sulfur;
D is a direct linkage, (C1-C8)-alkanediyl, (C5-C10)-arylene, O, NR2, CONR2, NR2CO, NR2C(O)NR2, NR2C(S)NR2, OC(O), C(O),CO,CS, S(O), S(O)2, S(O)2NR2, NR2S(O), NRS(O)2, S, CRCR, CC, NR2NCR2, NCR2, R2CN or CH(OH), which in each case can be substituted, once or twice, by (C1-C8)-alkanediyl, CR2CR3or (C5-C6)-arylene;
E is a direct linkage, (C1-C6)-alkanediyl, (C2-C6)-alkenediyll, (C2-C6)-alkynediyl, phenylene, phenylene-(C1-C3)-alkanediyl or (C1-C3)-alkanediyl-phenylene;
F is defined as D;
G is
115
L is C(R16) or N;
R0 is H, (C1-C8)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C1-C14)-aryl, (C5-C14 )-aryl-(C1-C8)-alkyl or (C1-C8)-alkyl-C(O), (C3-C12)-cycloalkyl-C(O), (C3-C12)-cycloalkyl-(C1-C6)-alkyl-C(O), (C5-C14)-aryl-C(O) or (C5-C14)-aryl-(C1-C6)-alkyl-C(O), with it being possible for the alkyl radicals to be substituted, once or more than once, by fluorine;
R1 is R2C(NR2)NR2, R2R3NC(NR2), R2R3NC(NR2)NR, or a 4 to 14-membered, monocyclic or polycyclic, aromatic or non-aromatic ring system which can optionally contain 1-4 heteroatoms from the group N, O and S and can optionally be substituted, once or more than once, by substituents from the group R12, R13, R14 and R15;
R2 and R3 are, independently of each other, H, (C1-C10)-alkyl, which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, H2N, R8ONR9, R8OR9, R6OC(O)R9, R8(C5-C14)-aryl-R9, R8R8NR9, HO(C1-C8)-alkyl-NR8R9, R8R8NC(O)R9, R8C(O)NR8R9, R8C(O)R9, R8R8NC(NR8), R8R8NC(NR8)NR8 or (C1-C18)-alkylcarbonyloxy-(C1-C6)-alkoxycarbonyl;
R4, R5, R6 and R7 are, independently of each other, H, fluorine, OH, (C1-C8)-alkyl, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, or R8OR9, R3SR9, R8CO2R9, R8OC(O)R9, R8(C5-C14)-aryl-R9, R8N(R2)R9, R8R8NR9, R8N(R2)C(O)OR9, R8S(O)nN(R2)R9, R8OC(O)N( R2)R9, to R8N(R2)C(O)N(R2)R9, R8N(R2)S(O)nN(R2)R9, R8S(O)nR9, R8SC(O)N(R2)R9, R8C(O)R9, R8N(R2)C(O)R9 or R8N(R2)S(O)nR9;
R8 is H, (C1-C8)-alkyl, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl or (C5-C14)-aryl-(C1-C8)-alkyl, with it being possible for the alkyl radicals to be substituted, once or more than once, by fluorine;
R9 is a direct linkage or (C1-C8)-alkanediyl;
R10 is C(O)R11, C(S)R11, S(O)nR11, P(O)nR11 or a four- to eight-membered, saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the group N, O and S;
R11 is OH, (C1-C8)-alkoxy, (C5-C14)-aryl-(C1-C8)-alkoxy, (C5-C14)-aryloxy, (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkoxy, (C5-C14)-aryl-(C1-C8)-alkylcarbonyloxy-(C1-C6)-alkoxy, NH2, mono- or di(C1-C8-alkyl)amino, (C5-C14)-aryl-(C1-C14)-alkylamino, (C1-C8)-dialkylamino-carbonylmethyloxy, (C5-C14)-aryl-(C1-C8)-dialkylaminocarbonylmethyloxy or (C5-C14)-arylamino or an L- or D-armino acid;
R12, R13, R14 and R15 are, independently of each other, H, (C1-C10)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycioalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, H2N, R8ONR9, R8OR9, R8OC(O)R9, R8R8NR9, R8(C5-C14)-aryl-R9, HO(C1-C8)-alkyl-N(R2)R9, R8N(R2)C(O)R9, R8C(O)N(R2)R9, R8C(O)R9, R2R3NC(NR2)NR2, R2R3NC(NR2), O or S; with it being possible for two adjacent substituents from the group R12 to R15 also together to be OCH2O, OCH2CH2O or OC(CH3)2O;
R16 is H, (C1-C10)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, (C2-C20)-alkenyl or (C2-C10)-alkynyl;
m is 1, 2, 3, 4, 5 or 6;
n is 1 or 2;
p and q are, independently of each other, 0 or 1; and the physiologically tolerated salts thereof,
with compounds being excluded in which R1ABDC(R16) or R1ABDC(R16)C is R1KC(R16) or R1KCHC (R16H), where, in this case,
R1 is XNHC(NH)(CH2)p, X1(NH(CH2)p or 4-imidazolyl-CH2, wherein p is an integer from 0 to 3,
X is hydrogen, (C1-C6)-alkyl, (C1-C6)-alkylcarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C18)-alkylcarbonyloxy-(C1-C6)-alkoxycarbonyl, (C6-C14)-arylcarbonyl, (C6-C14)-aryloxycarbonyl, (C6-C14)-aryl-(C1-C6)-alkoxycarbonyl, hydroxyl, (C1-C6)-alkoxy, (C6-C14)-aryl-(C1-C6)-alkoxy or amino, with the aryl groups in X being pure carbocycies which are optionally substituted once or more than once.
X1 is (C4-C14)-arylcarbonyl, (C4-C14)-aryloxycarbonyl, (C4-C14)-aryl-(C1-C6)-alkoxycarbonyl, (C4-C14)-aryl-(C1-C6)-alkoxy or RNHC(NR), where R and R have, independently of each other, the meanings of X and where the aryl groups in X1 are pure carbocycles which are optionally substituted once or more than once,
K is (C1-C6)-alkanediyl, (C3-C7)-cycloalkanediyl, phenylene, phenylene-(C1-C6)-alkanediyl, (C1-C6)-alkanediylphenylene, phenylene-(C2-C6)-alkenediyl or a divalent radical of a 5- or 6-membered, saturated or unsaturated ring which contains 1 or 2 nitrogen atoms and can be substituted, once or twice, by (C1-C6)-alkyl or doubly bonded oxygen or sulfur.
2. A compound of the formula I as claimed in claim 1 in which:
W is RABDC(R16), R1ABDC(R16)C,
116
where the ring systems
117
contain 1 or 2 heteroatoms from the group N and O, can be saturated or unsaturated once, and can be substituted by 1 or 2 substituents from R16;
Y is CO, CS or CH2;
Z is N(R0), O or CH2;
A is a direct linkage, (C1-C6)-alkanediyl, NR2NCR2, NR2C(O)NR2, NR2C(O)O, NR2C(O)S, NR2C(S)NR2, NR2C(S)O, NR2C(S)S, NR2S(O),NR2, NR2S(O)nO, NR2S(O)n, (C3-C8)-cycloalkanediyl, CC, NR2C(O), C(O)NR2, (C5-C12)-arylene-C(O)NR2, O, S(O)n, (C5-C12)-arylene-, CO, (C5-C12)-arylene-CO, NR2, SO2NR2, C(O)O, OC(O), NCR2, R2CN, CR2CR3, (C5-C12)-arylene-S(O)n, which in each case can be substituted by NR2 andor be substituted, once or twice, by (C1-C8)-alkanediyl;
B is a direct linkage, (C1-C6)-alkanediyl, (C5-C8)-arylene, (C3-C8)-cycloalkanediyl, CC, NR2, C(O), NR2C(O), C(O)NR2, NR2C(O)NR2, S(O), S(O)2, S(O)NR2, S(O)2NR2, NR2S(O), NR2S(O)2, O, CR2CR3, which in each case can be substituted, once or twice, by (C1-C6)-alkanediyl;
D is a direct linkage, (C1-C8)-alkanediyl, (C5-C8)-arylene, O, NR2, CONR2, NR2CO, NR2C(O)NR2, NR2C(S)NR2, OC(O), C(O)O, CO, CS, S(O), S(O)2, S(O)2NR2, NR2S(O), NR2S(O)2, S, CR2CR3, CC, NR2NCR2, NCR2, or R2CN, which in each case can be substituted, once or twice, by (C1-C6)-alkanediyl, CR2CR3 or (C5-C6)-arylene;
E is a direct linkage, (C1-C4)-alkanediyl, (C2-C4)-alkenediyl, (C2-C4)-alkynediyl, phenylene, phenylene-(C1-C2)-alkanediyl or (C1-C2)-alkanediylphenylene;
F is defined as D;
G is
118
L is C(R16) or N;
R0 is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C6)-alkyl, (C5-C12)-aryl, (C5-C12)-aryl-(C1-C6)-alkyl, (C1-C8)-alkyl-C(O), (C3-C8)-cycloalkyl-C(O), (C3-C8)-cycloalkyl-(C1-C4)-alkyl-C(O), (C5-C12)-aryl-C(O) or (C5-C12)-aryl-(C1-C14)-alkyl-C(O), where the alkyl radicals can be substituted, once or more than once, by fluorine;
R1 is R2C(NR2)NR3, R2R3NC(NR2), R2R3NC(NR2)NR2, or a 4-10-membered, monocyclic or polycyclic, aromatic or non-aromatic ring system which can optionally contain 1-4 heteroatoms from the group N, O and S and can optionally be substituted, once or more than once, by substituents from the group R12, R13, R14 and R15;
R2 and R3 are, independently of each other, H, (C1-C8)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C6)-alkyl, ( C5-C12)-aryl, (C5-C12)-aryl-(C1-C6)-alkyl, H2N, R8ONR9, R8OR9, R8OC(O)R9, R8(C5-C12)-aryl-R9, R8R8NR9, HO(C1-C8)-alkyl-NR8R9, R8R8NC(O)R9, R8C(O)NR8R9, R8C(O)R9, R8R8NC(NR8), R8R8NC(NR8)NR8 or (C1-C10)-alkylcarbonyloxy-(C1-C4)-alkoxycarbonyl;
R4, R5, R6 and R7 are, independently of each other, H, fluorine, OH, (C1-C8)-alkyl, (C5-C12)-cycloalkyl, (C5-C12)-cycloalkyl-(C1-C8)-alkyl, or R8OR9, R8SR9, R8CO2R9, R8OC(O)R9, R8(C5-C12)-aryl-R9, R8N(R2)R9, R8R8NR9, R8N(R2)C(O)OR9, R8S(O)nN(R2)R9, R8OC(O)N(R2)R9, R8C(O)N(R2)R9, R8N(R2)C(O)N(R2)R9, R8N(R2)S(O)nN(R2)R9, R8S(O)nR9, R8SC(O)N(R2)R9, R8C(O)R9, R8N(R2)C(O)R9, R8N(R2)S(O)nR9;
R8 is H, (C1-C6)-alkyl, (C5-C12)-cycloalkyl, (C5-C12)-cycloalkyl-(C1-C6)-alkyl, (C5-C12)-aryl or (C5-C12)-aryl-(C1-C6)-alkyl, where the alkyl radicals can be substituted, once or more than once, by fluorine;
R9 is a direct linkage or (C1-C6)-alkanediyi;
R10 is C(O)R11, C(S)R11, S(O)nR11, P(O)nR11 or a 4- to 8-membered, saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the group N, O and S;
R11 is OH, (C1-C6)-alkoxy, (C5-C12)-aryl-(C1-C6)-alkoxy, (C5-C12)-aryloxy, (C1-C6)-alkylcarbonyloxy-(C1-C4)-alkoxy, (C5-C12)-aryl-(C1-C6)-alkylcarbonyloxy-(C1-C6)-alkoxy, NH2, mono- or di(C1-C6-alkyl)amino, (C5-C12)-aryl-(C1-C6)-alkylamino or (C1-C6)-dialkylaminocarbonylmethyloxy;
R12, R13, R14 and R15 are, independently of each other, H, (C1-C8)-alkyl, which is optionally substituted, once or more than once, by fluorine, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C6)-alkyl, (C5-C12)-aryl, (C5-C12)-aryl-(C1-C6)-alkyl, H2N, R8ONR9, R8OR9, R8OC(O)R9, R8(C5-C12)-aryl-R9, R8R8NR9, HO(C1-C8)-alkyl-N(R2)R9, R8N(R2)C(O)R9, R8C(O)N(R2)R9, R8C(O)R9, R2R3NC(NR2), R2R3NC(NR3)NR2, O or S; where two adjacent substituents from the group R12 to R15 can also together be OCH2O, OCH2CH2O or OC(CH3)2O;
R16 is H, (C1-C8)-alkyl which is optionally substituted, once or more than once, by fluorine, (C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C6)-alkyl, (C5-C12)-aryl, (C5-C12)-aryl-(C1-C6)-alkyl, (C2-C8)-alkenyl or (C2-C8)-alkynyl;
m is 3,4 or 5;
n is 1 or 2; and
p and q are, independently of each other, 0 or 1. And the physiologically tolerated salts thereof.
3. A compound of the formula I as claimed in claim 1 in which:
W is R1AEDC(R16), R1ABDC(R16)C or
119
Y is CO, CS or CH2;
Z is N(R0) or CH2;
A is a direct linkage, (C1-C6)-alkanediyl, NR2NCR2, NR2C(O)NR2, NR2C(O)O, NR2C(O)S, NR2S(O)NNR2, NR2S(O)n, (C3-C6)-cycloalkanediyl, CC, NR2C(O), C(O)NR2, (C5-C10)-arylene-C(O)NR2, O, (C5-C10)-arylene-, CO, (C5-C10 )-arylene-CO, NR2, C(O)O, NCR2, R2CN or CR2CR3, which in each case can be substituted by NR2 andlor be substituted, once or twice, by (C1-C6)-alkanediyl;
B is a direct linkage, (C1-C6)-alkanediyl, (C5-C6)-arylene, (C5-C6)-cycloalkanediyl, CC, NR2C(O), C(O)NR2, NR2S(O)2, O or CR2CR3, which in each case can be substituted, once or twice, by (C1-C6)-alkanediyl;
D is a direct linkage, (C1-C6)-alkanediyl, (C5 -C6)-arylene, O, NR2, NR2CO, NR2C(O)NR2, NR2C(S)NR2, OC(O), C(O), S(O)2NR2, NR2S(O), NR2S(O)2, NCR2 or R2CN, which in each case can be substituted, once or twice, by (C1-C6)-alkanediyl;
E is a direct linkage, (C1-C4)-alkanediyl or (C2-C4)-alkenediyl;
F is a direct linkage, (C1-C6)-alkanediyl, O, CONR2, NR2CO, NR2C(O)NR2, OC(O), C(O)O, CO, S(O)2, S(O)2NR2, NR2S(O)2, CR2CR3, CC, NCR2 or R2CN, which in each case can be substituted, once or twice, by (C1-C6)-alkanediyl;
G is
120
L is C(R16) or N;
R0 is H, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C4)-alkyi, (C5-C10)-aryl, (C5-C10)-aryl-(C1-C4)-alkyl, (C1-C6)-alkyl-C(O), (C5-C6)-cycloalkylmethyl-C(O), phenyl-C(O) or benzyl-C(O), where the alkyl radicals can be substituted by 1-6 fluorine atoms;
R1 is R2C(NR2)NR2, R2R3NC(NR2),
121
with Y being NR2, O or S.
R2 and R3 are, independently of each other, H, (C1-C6)-alkyl which is optionally substituted, once or more than once, preferably 1-6 times, by fluorine, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C4)-alkyl, (C5-C10)-aryl, (C5-C10)-aryl-(C1-C4)-alkyl, H2N, R8OR9, R8(C5-C10)-aryl-R9, R8NHR9, R8R8NR9, R8NHC(O)R9, R8C(O), H2NC(NH) or H2NC(NH)NH;
R4, R5, R6 and R7 are, independently of each other, H, fluorine, OH, (C1-C6)-alkyl, (C6-C12)-cycloalkyl, (C6-C12)-cycloalkyl-(C1-C6)-alkyl, or R8OR9, R8CO2R9, R8OC(O)R9, R8-(C5-C10)-aryl-R9, R8NHR9, R8R8NR9, R8NHC(O)OR9, R8S(O)nNHR9, R8OC(O)NHR9, R8C(O)NHR9, R8C(O)R9, R8NHC(O)NHR9, R8NHS(O)nNHR9, R8NHC(O)R9, R8NHS(O)nR9;
R8 is H, (C1-C6)-alkyl, (C6-C12)-cycloalkyl, (C6-C12)-cycloalkyl-(C1-C4)-alkyl, (C5-C10)-aryl or (C5-C10)-aryl-(C1-C4)-alkyl, where the alkyl radicals can be substituted by 1-6 fluorine atoms;
R9 is a direct linkage or (C1-C6)-alkanediyl;
R10 is C(O)R11, S(O)nR11 or P(O)nR11:
R11 is OH, (C1-C6)-alkoxy, (C5-C10)-aryl-(C1-C6)-alkoxy, (C5-C10)-aryloxy, (C1-C6)-alkylcarbonyloxy-(C1-C4)-alkoxy, (C5-C10)-aryl-(C1-C4)-alkylcarbonyloxy-(C1-C4)-alkoxy, NH2 or mono- or di(C1-C6-alkyl)-amino;
R12, R13 and R14 are H, (C1-C6)-alkyl, which is optionally substituted, once or more than once, by fluorine, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C4)-alkyl, (C5-C10)-aryl, (C5-C10)-aryl-(C1-C4)-alkyl, H2N, R8OR9, R8OC(O)R9, R8-(C5-C10)-aryl-R9, R8R8NR9, R8NHC(O)R9, R8C(O)NHR9, H2NC(NH), H2NC(NH)NH or O; where two adjacent substituents from the group R12 to R14 can also together be OCH2O or OCH2CH2O;
R16 is H, (C1-C6)-alkyl which can be substituted 16 times by fluorine, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C4)-alkyl, phenyl, phenyl-(C1-C4)-alkyl or (C2-C6)-alkenyl;
m is 3,4 or 5;
n is 1 or 2; and
p and q are, independently of each other, 0 or 1, and the physiologically tolerated salts thereof.
4. A compound of the formula I as claimed in claim 1 , in which:
W is R1AEDC(R16) or R1ABDCHC,
Y is CO or CS;
Z is N(R0);
A is a direct linkage, (C1-C4)-alkanediyl, NR2NCR2, NR2C(O)NR2, NR2C(O)O, NR2S(O)n, NR2S(O)nNR2, NR2CO, NR2 or NCR2, which in each case can be substituted by NH andor be substituted, once or twice, by (C1-C4)-alkanediyl;
B is a direct linkage, (C1-C4)-alkanediyl, phenylene, a divalent radiical of pyridine, thiophene or furane, cyclohexanediyl, CC, CR2CR3, C(O)NR2 or NR2C(O), which in each case can be substituted, once or twice, by (C1-C4)-alkanediyl;
D is a direct linkage, (C1-C4)-alkanediyl, phenylene, O, NR2, NR2CO, NR2C(O)NR2, R2NS(O)2NR2, NR2S(O)2, NR2S(O), NCR2 or R2CN, which in each case can be substituted, once or twice, by (C1-C4)-alkanediyl;
E is a direct linkage or (C1-C4)-alkanediyl;
F is a direct linkage, (C1-C6)-alkanediyl, O, CONR2, NR2CO, NR2C(O)NR2, S(O)2NR2, NR2S(O)2, CR2CR3, CC, NCR2 or R2CN, which in each case can be substituted, once or twice, by (C1-C4)-alkanediyl;
G is
122
R0 is H, (C1-C6)-alkyl, trifluoromethyl, pentafluoroethyl, (C5-C6)-cycloalkyl, (C5-C6)-cycloalkyl-(C1-C2)-alkyl, optionally substituted phenyl or benzyl which is optionally substituted on the phenyl radical;
123
R2 and R3 are, independently of each other, H, (C1-C6)-alkyl, trifluoromethyl, pentafluoroethyl, (C5-C6)-cycloalkyl, (C5-C6)-cycloalkyl-(C1-C2)-alkyl, phenyl, benzyl, H2N, R8OR9, R8(C5-C10)-aryl-R9, R8NHR9, R8R8NR9, R8NHC(O)R9, H2NC(NH) or H2CC(NH)NH;
R4, R5, R8 and R7 are, independently of each other, H, fluorine, OH, (C1-C6)-alkyl, (C10-C12)-cycloalkyl, (C10-C12)-cycloalkyl-(C1-C6)-alkyl, or R80R9, R8-(C5-C10)-aryl-R9, R8R8NR9, R8NHC(O)OR9, R8S(O)nNHR9, R8OC(O)NHR9 or R8C(O)NHR9;
R8 is H, (C1-C6)-alkyl, (C10-C12)-cycloalkyl, (C10-C12)-Cycloalkyl-(C1-C2)-alkyl, (C5-C10)-aryl or (C5-C10)-aryl-(C1-C2)-alkyl;
R9 is a direct linkage or (C1-C6)-alkanediyl,
R10 is C(O)R11;
R11 is OH, (C1-C6)-alkoxy, phenoxy, benzyloxy, (C1-C4)-alkylcarbonyloxy-(C1-C4)-alkoxy, NH2, mono- or di(C1-C8-alkyl)amino;
R16 is H, (C1-C4)-alkyl, trifluoromethyl, pentafluoroethyl, (C5-C6)-cycloalkyl, (C5-C6)-cycloalkyl-(C1-C2)-alkyl, phenyl or benzyl;
n is 1 or 2; and
p and q are, independently of each other, 0 or 1, and the physiologically tolerated salts thereof.
5. A process for preparing a compound of formula I as claimed in claim 1 wherein F is C(O)NR2, comprising linking a compound of formula II
124
wherein M is hydroxycarbonyl, (C1-C6)-alkoxycarbonyl, or an activated carboxylic acid derivative, and W, Z, Y, and E are as defined in claim 1, with HNR2G, wherein G and R2 are as defined in claim 1.
6. A pharmaceutical composition comprising a vitronectin receptor antagonistic amount of the compound of claim 1, and a pharmaceutically acceptable carrier.
7. A method of treating a disease or condition associated with vitronectin receptor binding comprising administering to a mammal the composition of claim 6.
8. A method of treating a disease or condition associated with the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes, comprising the administration of the compound of claim 1 to a mammal, wherein said disease or condition is selected from the group consisting of reabsorption by osteoclasts, tumor growth and tumor metastasis, inflammation, cardiovascular disease, nephropathies and retinopathies.